Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Europe’s BAPS Swaminarayan Sanstha is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.

Exterior of the Hindu temple, BAPS Shri Swaminarayan Mandir, in Neasden, London © Shutterstock
The Neasden Temple, London

Led by Oxford University researchers, the PRINCIPLE trial is working across all UK communities to evaluate if treatment administered early in the course of the Covid-19 illness can help people aged over 50 recover quickly, without the need for hospital admission.

Sadhu Yogvivekdas, Head of the BAPS Shri Swaminarayan Sanstha, UK & Europe, explained details of the trial to its vast network of worshipers and followers as part of an online sermon, explaining that those with Covid-19 symptoms can join online from home or via GP practices across the country, without the need for face-to-face visits.

While developing grassroots partnerships has been a major focus of the trial’s recruitment strategy so far, recruiting people from Black, Asian and minority ethnic communities has been a particular challenge.

The full story is available on the Nuffield Department of Primary Care Health Sciences website

Find out more about the PRINCIPLE trial

 

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.